ISAKOS: 2019 Congress in Cancun, Mexico
ISAKOS

2019 ISAKOS Biennial Congress ePoster #1040

 

Delay of Cartilage Degeneration of Polyurethane Meniscal Substitute Alone or Enhanced with Autologous Mesenchymal Stem Cells Evaluated with T2-Mapping at 24 Follow-Up Months

Anell Olivos-Meza, PhD, Mexico City MEXICO
Ana Luisa Bravo-Mercado, MD, Mexico City MEXICO
Carlos Landa Solis, PhD, Mexico City, Mexico city MEXICO
Socorro Cortes, MD, Mexico City, San cristobal xochim MEXICO
Pedro Rojas, MD, Puebla MEXICO
Jonatan J. Hernández-León, MD, Mexico City MEXICO
Victor Hugo Cardenas, MD, Ciudad De Mexico, Ciudad de Mexico MEXICO
Brenda Olivos Diaz, VMD, Mexico City, Mexico city MEXICO
Saul Renan, MD, Mexico City MEXICO
Francisco Perez-Jimenez, MD, Mexico City MEXICO
Clemente Ibarra, MD, Mexico City MEXICO

Instituto Nacional de Rehabilitación, Mexico City, Mexico City, MEXICO

FDA Status Cleared

Summary

No deterioration in cartilage was observed from 3 to 24 months in both groups (p>0.05), however when comparing scaffolds with and without cells t2-mapping was significantly stable in the femur for MS-A and tibial plateau for MS-MSC. No deterioration of cartilage status was observed in any of the groups after 24 months.

Abstract

Purpose

To evaluate the protective effect in the adjacent cartilage of polyurethane meniscal substitute alone or enhanced with autologous mesenchymal stem cells with T2-mapping at 24 follow-up months.

Methods

Seventeen patients with a history of partial meniscectomy underwent to polyurethane meniscal substitute (Actifit®) alone (MS-A) or enhanced with mobilized mesenchymal stem cells (MS-MSC). In the MS-MSC, three doses of 300mcg of Granulocyte Colony Stimulating Factor (G-CSF) were injected, at day 4 a buffy coat with mobilized MSC was obtained in peripheral blood, those cells were seeded in the meniscal substitute. The meniscal substitute was implanted by arthroscopy and concomitant lesions were treated. T2 mapping and clinical knee scores were applied.

Results

Ages were similar (37.2 MS-MSC /33.17 MS-A) in a total of 11 vs 6 patients, respectively. Significant improvement in all functional scores was observed in both groups at pre-op vs 24 months (p<0.05). Cartilage status by T2-maping at 3 & 24 months MS-MSC (f=49.5? 2.6 vs 51.1?2.6; t=47.17?3.7 vs 40.8? 1.6) and MS-A (f=47.1? 2.8 vs 41.7?2.6, t=46.25?6.3 vs 47.4?1.6) in the femur & tibia, respectively. Comparing T2-maping in femur (MS-MSC 51.1?2.6 vs MS-A 41.7?2.6, p=0.04) and tibia (MS-MSC 40.8? 1.6 vs MS-A 47.4?1.6, p=0.02).

Conclusions

No deterioration in cartilage was observed from 3 to 24 months in both groups (p>0.05), however when comparing scaffolds with and without cells t2-mapping was significantly stable in the femur for MS-A and tibial plateau for MS-MSC. No deterioration of cartilage status was observed in any of the groups after 24 months.